These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38341165)

  • 1. Sustained hypophosphatemia after denosumab in a patient on hemodialysis.
    Almodares AAS; Elder GJ; Abrahamsen B
    Bone; 2024 Apr; 181():117045. PubMed ID: 38341165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
    Watkins KR; Rogers JE; Atkinson B
    Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome.
    Chung TL; Chen NC; Chen CL
    Osteoporos Int; 2019 Feb; 30(2):519-523. PubMed ID: 30171299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
    Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
    Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes of serum calcium and bone turnover markers in maintenance hemodialysis patients treated with denosumab].
    Wang Y; Zhu L; Yang B; Gan LY; Zuo L
    Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):594-597. PubMed ID: 36822871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V; Chiang CY; Booth J; Mount PF
    Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe hypocalcaemia and hypophosphataemia following intravenous iron and denosumab: a novel drug interaction.
    Smyth B; Ong S
    Intern Med J; 2016 Mar; 46(3):360-3. PubMed ID: 26968599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
    Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
    J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
    Hiramatsu R; Ubara Y; Sawa N; Sakai A
    Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
    Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
    JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
    Yasuda Y; Iwama S; Arima H
    Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
    Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK
    J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab-induced hypocalcemia post bariatric surgery-a severe and protracted course: a case report.
    Awang MH; Hatta SFWM; Mohamad AF; Ghani RA
    J Med Case Rep; 2023 Mar; 17(1):73. PubMed ID: 36859300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.
    Spångeus A; Rydetun J; Woisetschläger M
    Osteoporos Int; 2024 Jan; 35(1):173-180. PubMed ID: 37750930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
    Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
    Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
    Park SY; Kim J; Chung HY
    Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
    Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
    Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
    Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
    J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.